Is Spruce Biosciences, Inc. (SPRB) a Buy, Sell, or Hold?
NASDAQ : SPRB
Spruce Biosciences, Inc.
$47.07 USD
$0.66 (1.42%)
- Volume
- 26.08K
- Average Volume
- 70.76K
- Market Capitalization
- $129.55M
- P/E Ratio
- -1.15
- Dividend Yield
- 0.00%
- Price Target
- $140.00
- Year High
- $240.00
- Year Low
- $7.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $9.23
Company Overview
NASDAQ
Javier Szwarcberg
Biotechnology
Healthcare
SPRB
14
US
USD
Liquidity Metrics
0.03
9.23
9.23
8.78
0.00
Sales & Valuation
-$
0.00
1.37
-3.03
-17.59
Profitability
-$50.83
-$38.97M
0.00%
0.00%
-84.49%
-34.15%
P/E Metrics
-1.15
-0.02
-0.02
Analyst Price Target & Rating
$140.00
$150.00
$123.00
3/5
11 Analysts
-66.38%
Financial Health Scores
-6.97
2/9
$43.25M
$56.17M
$21.52M
-$36.46M
Key Metrics (TTM)
$80.78M
0.00
-2.23
4.67
-155.40%
-74.40%
-58.40%
-22.97%
0 days
Company Executives
| Name | Title |
|---|---|
| Daven Mody | Senior Vice President of Regulatory & Quality |
| Kirk Ways | Chief Medical Officer & Director |
| Michael G. Grey | Executive Chairman |
| Corwin Dale Hooks | Chief Commercial Officer |
| Samir Gharib | President & Chief Financial Officer |
| Javier Szwarcberg | Chief Executive Officer & Director |
| Bruno Gagnon BPHARM | Senior Vice President of Clinical Development Operations |
Poll Results
No votes yet today — be the first to share your view!
About Spruce Biosciences, Inc. (NASDAQ:SPRB) Stock
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from p ... olycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
2026-08-12 09:00:00
Spruce Biosciences, Inc. (Nasdaq: SPRB) a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disord
2026-08-12 08:00:00
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB) a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Cure Sanfilippo Foundation and the National MPS Society have agreed to make a combined $5.5 million strategic investment in Spruce. The proceeds will be used to partially fund TA-ERT EAP, helping to broaden patient access to invest.
Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development
2026-08-03 08:00:00
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development, effective today. Dr. Cohen Pfeffer brings more than a decade of biopharmaceutical industry experience spanning c.
Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer
2026-07-27 08:00:00
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences” or “Spruce”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Dr. Quartel brings more than 25 years of experience in the international pharmaceutical industry, with senior r.
2026-07-08 16:01:00
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit, in a fireside chat hosted by Madison El-Saadi, Ph.D., Healthcare Research Analyst.T.
Spruce Biosciences Possibly First In-MPS IIIB Class Enzyme Replacement Therapy
2026-07-08 04:11:19
Spruce Biosciences offers a high-risk, high-reward opportunity as it advances TA-ERT, potentially the first disease-modifying therapy for MPS IIIB, toward FDA approval. TA-ERT demonstrated durable normalization of key biomarkers and stabilization of cognitive and motor function over six years, supporting its accelerated approval pathway. SPRB is preparing a BLA submission in Q4, with FDA feedback suggesting acceptance of CSF HS-NRE as a surrogate endpoint; no further clinical studies are expected pre-submission.
Spruce Biosciences Joins the Russell 3000® Index
2026-06-29 08:00:00
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological diso
Spruce Biosciences Joins the Russell 3000® Index
2026-06-29 08:00:00
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has been added as a member of the Russell 3000® Index, effective with the opening of U.S. equity markets today, in connection with the 2026 Russell U.S. Indexes Reconstitution. The Russell 3000® Index measures the performance o.
Frequently Asked Questions
-
What is the current Spruce Biosciences, Inc. (SPRB) stock price?
-
Spruce Biosciences, Inc.(NASDAQ:SPRB) stock price is $47.07 in the last trading session. During the trading session, SPRB stock reached the peak price of $240 while $7 was the lowest point it dropped to. The percentage change in SPRB stock occurred in the recent session was 1.42% while the dollar amount for the price change in SPRB stock was $0.66.
-
SPRB's industry and sector of operation?
-
The NASDAQ listed SPRB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of SPRB?
-
Daven Mody | Senior Vice President of Regulatory & Quality
Kirk Ways | Chief Medical Officer & Director
Michael G. Grey | Executive Chairman
Corwin Dale Hooks | Chief Commercial Officer
Samir Gharib | President & Chief Financial Officer -
How many employees does SPRB have?
-
Number of SPRB employees currently stands at 14. SPRB operates from 611 Gateway Boulevard, South San Francisco, CA 94080, US.
-
Link for SPRB official website?
-
Official Website of SPRB is: https://www.sprucebio.com
-
How do I contact SPRB?
-
SPRB could be contacted at phone #415 655 4168 and can also be accessed through its website. SPRB operates from 611 Gateway Boulevard, South San Francisco, CA 94080, US.
-
How many shares of SPRB are traded daily?
-
The average number of SPRB shares traded daily for last 3 months was 70.76K.
-
What is the market cap of SPRB currently?
-
The market value of SPRB currently stands at $129.55M with its latest stock price at $47.07